Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers aim to determine how baseline (pre-conceptional) uterine perfusion characteristics affect implantation rates and obstetric complications in women who underwent high-quality blastocyst transfer.
In hormonally prepared frozen embryo transfer cycles, basal bilateral uterine artery Doppler velocimetry will be performed before treatment (pre-conceptional) in each patient. Only patients who have high-quality blastocyst stage embryos will be included in the study. Since the implantation potential of the specified embryos is high, possible embryo-induced implantation failure would be minimized.
Bilateral uterine artery Doppler velocimetry will be performed during the basal ultrasonography (on the 2-5th day of menstruation). Any uterine artery notch, absent diastolic or reverse flow also will be recorded. In addition, sub-endometrial (arcuate artery) blood flows will be evaluated by Doppler ultrasonography.
For endometrial preparation, estrogen replacement will be given for approximately 12-14 days as a routine In cases with endometrial thickness ≥7mm, progesterone treatment will be started and embryo transfer will be planned on the 6th day of the treatment.
A pregnancy test will be performed 9 days after embryo transfer. Pregnant patients will be called for ultrasonography control 3 weeks later to determine fetal heartbeat. Additionally, the patients will be followed till labor and any obstetric complications will be recorded.
Uterine artery Doppler ultrasonography findings in patients with and without pregnancy will be compared. Additionally, in the group in which pregnancy was achieved, obstetric results including birth weight, small-large for gestational age, presence of hypertension, and preterm labor will be correlated with baseline (pre-conceptional) uterine artery Doppler parameters.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| non-pregnant | negative b-hCG results 9 days after embryo transfer. | ||
| pregnant with obstetric complications | Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks. | ||
| pregnant without obstetric complications | Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Live Birth Rate | pregnancy beyond 24 weeks of gestational age. | 9 months |
| Obstetric Complication Rates | Conditions such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. that develop during pregnancy | 24th gestational weeks till delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Positive β-hCG results | Positive β-hCG results nine days after embryo transfer. | Nine days after each embryo transfer |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All patients who have artificial endometrial preparation with high-quality blastocysts between May 2022 and December 2022 will be included. All included patients will have bilateral uterine artery Doppler velocimetry on 2-5 days of their menstrual cycle by transvaginal ultrasonography.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ŞAFAK OLGAN, MD | Contact | 00905064068740 | safakolgan@gmail.com | |
| ARİF C ÖZSİPAHİ, MD | Contact | 005068301073 | a.canozsipahi@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| ŞAFAK OLGAN, MD | Akdeniz University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Akdeniz University | Recruiting | Antalya | 07700 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided